Aspect Biosystems Ltd.: federal grants and contributions: 24 agreements; $63.8M value; 5 departments; 9 programs.
Assay record ASY-CA-0WOLJ090GI · Cite as: Assay Systems, “Aspect Biosystems Ltd.: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/aspect-biosystems-ltd/
Project Podium: Establish a world-leading biomanufacturing facility & capabilities to advance and produce bioprinted tissue therapeutics in Canada
Increase sales of bioprinter technology services through improved business processes
Commercialize an innovative 3D bioprinting platform for manufacturing human tissue
Commercialize an innovative 3D bioprinting platform for manufacturing human tissue
Support Aspect Biosystems Ltd. to continue operations during the COVID-19 pandemic
This project will support the firm to achieve key development and regulatory milestones for their bioprinted pancreatic tissue therapeutic for Type 1 Diabetes to advance to final IND-enabling studies, and to demonstrate their 3D bioprinting technology is a biomanufacturing platform by showing efficacy of bioprinted liver tissues in multiple liver diseases.
This project will involve the development of novel 3D printing technologies (including hardware, software, biomaterials, and methods) to enable the fabrication of implantable tissues that can engraft and be vascularized in vivo.
CIIP Korea project 3D Printing Therapy will integrate unique 3D bioprinting technology from Aspect Biosystems Ltd. (Canada) with pluripotent stem cell technology from NEXEL Co., Ltd. (Korea) and tissue engineering technologies from POSTECH (Korea). Together, this international team will create a comprehensive solution for 3D bioprinting implantable cardiac and pancreatic therapeutic tissues containing validated stem cell-derived cells as an important step towards the future treatment of patients with myocardial infarction or Type-1 Diabetes.
This project involves the development of scalable manufacturing processes and improved automation systems for the firm's novel microfluidics-based 3D bioprinter platform that are necessary for the successful and profitable commercial launch of the bioprinter and associated consumables.
This international collaborative project integrates innovative Canadian bioprinting technology with unique cell immortalization and tissue technology from Germany in order to generate and validate a portfolio of highly physiological and functional living bioprinted 3D human tissues.
The proposed CanExport project addresses Aspect Biosystems’ international growth strategy of our microfluidic 3D bioprinting technology through market awareness and partnerships in targeted regions of the United States and Europe.
The purpose of this CanExport SMEs agreement is to support small- and medium-sized enterprises (SMEs) for activities related to export market development that are part of an export business case for a specific target market, particularly where activities are targeting departmental priority markets and sectors.
This Youth project will provide employment for a recent graduate in the role of a production analyst for novel microfluidic devices.
Carbon Connect is an innovative, emissions management service package providing oil and gas producers with compliance systems, strategies and implementation of Canadian emissions reduction technologies.
Subsidy payments to industry for research and deve
The purpose of the Canadian International Innovation Program (CIIP) contribution agreement is to support Canadian SMEs identify international partners in CIIP target countries for industrial research and development collaboration that has good potential for commercialization.
All grants from Innovation, Science and Economic Development Canada
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.